A peptide
reading guide
GROWTH-HORMONE PEPTIDES / SIDE-BY-SIDE
Compare growth-hormone peptides: short chains of protein building blocks linked to hormone signals. See what each is, where the evidence stops and what needs medical review. This is a reading aid, with no ranking or personal recommendations.
NXT LVL may earn money when readers become Promise patients.
Promise prescribes now. A licensed U.S. provider reviews each request and decides whether to prescribe. Not everyone qualifies. Compounded medicines are made to order and are not FDA-approved.
U.S. patients only. Availability varies by state and by treatment. Promise does not offer care outside the U.S.
A secretagogue prompts a gland to release a hormone. These peptides use signals linked to growth hormone, made by the pituitary gland beneath the brain. They are not growth hormone itself. The shared pathway does not give them the same evidence or legal status.
Compounded means prepared to order. FDA, the U.S. drug regulator, has not approved compounded medicines. The pharmacy's ingredient rules apply separately from a provider's decision about a person.
This name describes a combination, not the approved tesamorelin product. Approval of a single finished medicine does not extend to a blend with another peptide. Ipamorelin adds its own evidence gaps and FDA safety concerns.
Promise lists these options for provider review. A licensed U.S. provider decides whether to prescribe. The listing does not change FDA status or the rules for the exact ingredient.
NXT LVL may earn money when readers become Promise patients.
Promise lists tesamorelin + ipamorelin. A licensed U.S. provider decides; not everyone qualifies. FDA still lists ipamorelin acetate in Category 2, its safety-concern group, for 503B only: larger compounding facilities. This is not a 503A Category 2 listing.
FDA's page current as of April 22, 2026 lists CJC-1295 among withdrawn nominations. It lists ipamorelin acetate both there and in Category 2, a safety-concern group for larger compounding facilities. A withdrawn nomination is not clearance, and FDA gives no individual withdrawal dates.
A page on a commercial website cannot change those facts. The beginner questions explain the difference between a product listing, a prescription decision and lawful pharmacy preparation.
FDA reports serious reactions linked to CJC-1295, including a faster heart rate and flushing. It also notes dizziness and low blood pressure. FDA warns that the immune system may react to the peptide.
FDA is concerned that injected ipamorelin could trigger an immune reaction. No human study has checked its safety when injected under the skin.
In a study that gave ipamorelin into a vein, two patients died after complications of cancer surgery. FDA says it is unclear whether ipamorelin played a part.
Promise lists these options for provider review. A licensed U.S. provider decides whether to prescribe. The listing does not change FDA status or the rules for the exact ingredient.
NXT LVL may earn money when readers become Promise patients.
Promise lists ipamorelin. A licensed U.S. provider decides; not everyone qualifies. FDA still lists ipamorelin acetate in Category 2, its safety-concern group, for 503B only: larger compounding facilities. This is not a 503A Category 2 listing.
A Promise visit starts a request for review. A licensed U.S. provider decides whether to prescribe. Not everyone qualifies, and no particular treatment is promised.
NXT LVL may earn money when readers become Promise patients.
Promise prescribes these peptides now through licensed U.S. providers. A provider reviews every request and decides. Not everyone qualifies.
U.S. patients only. Availability varies by state and by treatment. Promise does not offer care outside the U.S.
